Ulcerative Colitis
MRM Health Nets $64M and Treeline Gathers $200M: Fierce Biotech Fundraising Tracker 2025
MRM Health; Series B Funding; Microbiome therapeutics; Ulcerative colitis; Live Biotherapeutic Product (LBP); Biocodex; Treeline; Biotech fundraising; IBD therapy
Abivax aces pair of phase 3 ulcerative colitis trials as end of cash runway looms
Abivax; Obefazimod; ulcerative colitis; Phase 3 trial; clinical remission; ABTECT-1; ABTECT-2; cash runway; induction trials; oral miR-124 enhancer; maintenance trial
Sanofi and Teva Pioneer Next-Generation IBD Treatment with Promising TL1A Antibody Results
Inflammatory Bowel Disease (IBD), TL1A Antibody, Duvakitug, Crohn’s Disease, Ulcerative Colitis, Precision Medicine, Immunology, Gastrointestinal Diseases
FDA Approves TREMFYA (Guselkumab) for Moderately to Severely Active Ulcerative Colitis
TREMFYA, Guselkumab, FDA Approval, Ulcerative Colitis, Inflammatory Bowel Disease, Johnson & Johnson
Johnson & Johnson’s TREMFYA Receives FDA Approval for Ulcerative Colitis, Expanding Treatment Options
TREMFYA, guselkumab, FDA approval, ulcerative colitis, inflammatory bowel disease, Johnson & Johnson